Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RVLP

RVL Pharmaceuticals (RVLP) Stock Price, News & Analysis

RVL Pharmaceuticals logo

About RVL Pharmaceuticals Stock (NASDAQ:RVLP)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.00
$0.19
52-Week Range
N/A
Volume
63.96 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Receive RVLP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RVL Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RVLP Stock News Headlines

Raval ICS Ltd.
New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
RVLPQ RVL Pharmaceuticals plc
RVL Pharmaceuticals PLC RVLPQ
See More Headlines

RVLP Stock Analysis - Frequently Asked Questions

RVL Pharmaceuticals plc (NASDAQ:RVLP) posted its quarterly earnings results on Monday, March, 20th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.03. The company earned $9.81 million during the quarter, compared to analyst estimates of $12.10 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that RVL Pharmaceuticals investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Cardiff Oncology (CRDF), Osmotica Pharmaceuticals (OSMT), AbCellera Biologics (ABCL), Amarin (AMRN) and Coda Octopus Group (CODA).

Company Calendar

Last Earnings
3/20/2023
Today
6/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RVLP
Fax
N/A
Employees
125
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$49.72 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
106,504,000
Optionable
Optionable
Beta
N/A
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:RVLP) was last updated on 6/12/2025 by MarketBeat.com Staff
From Our Partners